The Pfizer/BioNTech submitted today to the US Federal Food and Drug Administration (FDAthe initial data of their tests for its administration vaccinethem against coronavirus in childrenaged 5 to 11 years, announcing, at the same time, that they will formally submit a request for its approval, for urgent use, in the coming weeks.
According to APE BPE, citing Reuters, the cases between the children increased and peaked in early September, according to the American Academy of Pediatrics.
It elicits a strong immune response
This vaccine, which has already been authorized for administration to teenagers 12 to 15years and it has been approvedfully for ages 16 and up, showed a strong immune response in this age group in a clinical trial of 2,268 participants, Pfizer / BioNTech announced on September 20.
This vaccine was approved for use in children aged 12-15 years about a month after the companies applied for it. If the same schedule is followed for this application, it may be possible for children aged 5 to 11 years to start being vaccinated by end of October.
A quick approval would help prevent a possible increase in cases in the autumn, as the schools have already opened across the country, writes the international news agency.
While children are in danger less In severe cases of COVID-19, minors can transmit the virus to others, including vulnerable groups at higher risk of becoming seriously ill.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
